Protara Therapeutics (FRA:1KPA) Beginning Cash Position: €13.44 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1KPA Protara Therapeutics Inc FRA:1KPA
34 GF Score
Price €3.14
! 3 Warning Signs
View Full Analysis

What is Protara Therapeutics Beginning Cash Position?

Protara Therapeutics FRA:1KPA -1.87% 34 Beginning Cash Position is €13.44 Mil as of Jun. 2026. GuruFocus rates FRA:1KPA with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

Protara Therapeutics's Beginning Cash Position for the quarter that ended in Jun. 2026 was €13.44 Mil.

Protara Therapeutics's quarterly Beginning Cash Position increased from Dec. 2025 (€11.35 Mil) to Mar. 2026 (€43.60 Mil) but then declined from Mar. 2026 (€43.60 Mil) to Jun. 2026 (€13.44 Mil).

Protara Therapeutics's annual Beginning Cash Position increased from Dec. 2023 (€22.81 Mil) to Dec. 2024 (€38.52 Mil) and increased from Dec. 2024 (€38.52 Mil) to Dec. 2025 (€139.67 Mil).

Protara Therapeutics Beginning Cash Position Related Terms

Protara Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Protara Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protara Therapeutics Beginning Cash Position Chart

Protara Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 149.91 34.43 22.81 38.52 139.67

Protara Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 79.94 27.47 11.35 43.60 13.44
FRA:1KPA
34GF Score
Protara Therapeutics Inc FRA:1KPA
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protara Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €13.44 Mil mean?
Protara Therapeutics (FRA:1KPA) has a Beginning Cash Position of €13.44 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Protara Therapeutics and its competitors.
Is Protara Therapeutics' Beginning Cash Position too high?
Protara Therapeutics' current Beginning Cash Position is €13.44 Mil. Overall, Protara Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Protara Therapeutics' Beginning Cash Position compare to TRDA and ACIU?
Protara Therapeutics' Beginning Cash Position of €13.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Protara Therapeutics and its competitors. Protara Therapeutics's current Beginning Cash Position is €13.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protara Therapeutics stock overvalued right now?
Protara Therapeutics (FRA:1KPA) has a current Beginning Cash Position of €13.44 Mil. The current Beginning Cash Position is €13.44 Mil. Protara Therapeutics' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Protara Therapeutics (FRA:1KPA), the current Beginning Cash Position is €13.44 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Protara Therapeutics Business Description

Other Exchanges TARA:USA
Address 345 Park Avenue South, 3rd Floor, New York, NY, USA, 10010
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
34GF Score

Get the complete analysis for FRA:1KPA

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.14
Price